These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 11709805)

  • 21. Comparison of renin-angiotensin to calcium channel blockade in renal disease.
    Tikkanen I; Johnston CI
    Kidney Int Suppl; 1997 Dec; 63():S19-22. PubMed ID: 9407414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases.
    Border WA; Noble N
    Semin Nephrol; 2001 Nov; 21(6):563-72. PubMed ID: 11709804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers.
    Weir MR; Henrich WL
    Curr Opin Nephrol Hypertens; 2000 Jul; 9(4):403-11. PubMed ID: 10926177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Control of blood pressure by the renin-angiotensin-aldosterone system.
    Hall JE
    Clin Cardiol; 1991 Aug; 14(8 Suppl 4):IV6-21; discussion IV51-5. PubMed ID: 1893644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of angiotensin II in glomerular injury.
    Ma L; Fogo AB
    Semin Nephrol; 2001 Nov; 21(6):544-53. PubMed ID: 11709802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of aldosterone in the remnant kidney model in the rat.
    Greene EL; Kren S; Hostetter TH
    J Clin Invest; 1996 Aug; 98(4):1063-8. PubMed ID: 8770880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The renin-angiotensin system].
    Hilgers KF
    Urologe A; 2009 Aug; 48(8):925-33; quiz 934-5. PubMed ID: 19669119
    [No Abstract]   [Full Text] [Related]  

  • 28. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
    Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
    Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
    Slagman MC; Navis G; Laverman GD
    Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease.
    Jensen J; Henik RA; Brownfield M; Armstrong J
    Am J Vet Res; 1997 May; 58(5):535-40. PubMed ID: 9140564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin converting enzyme inhibition and the kidney.
    Hollenberg NK
    Curr Opin Cardiol; 1988; 3(Suppl 1):S19-29. PubMed ID: 11538849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications.
    Epstein M
    Am J Kidney Dis; 2001 Apr; 37(4):677-88. PubMed ID: 11273866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin II receptor blockade in diabetic nephropathy.
    Andersen S
    Dan Med Bull; 2004 Aug; 51(3):274-94. PubMed ID: 16009059
    [No Abstract]   [Full Text] [Related]  

  • 34. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.
    Duprez DA
    J Hypertens; 2006 Jun; 24(6):983-91. PubMed ID: 16685192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.
    Li XC; Zhang J; Zhuo JL
    Pharmacol Res; 2017 Nov; 125(Pt A):21-38. PubMed ID: 28619367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The benefits of angiotensin II receptor blockers in patients with renal insufficiency or failure.
    Venkata C; Ram S; Fierro G
    Am J Ther; 1998 Mar; 5(2):101-5. PubMed ID: 10099045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin II and its receptors in the diabetic kidney.
    Burns KD
    Am J Kidney Dis; 2000 Sep; 36(3):449-67. PubMed ID: 10977776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue renin angiotensin systems: theoretical implications for the development of hyperkalemia using angiotensin-converting enzyme inhibitors.
    Schlueter W; Keilani T; Batlle DC
    Am J Med Sci; 1994 Feb; 307 Suppl 1():S81-6. PubMed ID: 8141171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Independent regulation of renin-angiotensin-aldosterone system in the kidney.
    Nishiyama A; Kobori H
    Clin Exp Nephrol; 2018 Dec; 22(6):1231-1239. PubMed ID: 29600408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
    Bomback AS; Toto R
    Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.